Fibrinogen poissy I: A new case of the Aα Arg 16His fibrinogen variant

Blood Coagulation and Fibrinolysis

Volumn 8, Issue 7, 1997, Pages 441-444

  Mathonnet, F ^a   Guillon, L ^b   Detruit, H ^c   Van Amerongen, G ^b   Denninger, M H ^d   Giudicelli, Y ^a,e   De Mazancourt, P ^b,e  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^d BEAUJON HOSPITAL   (France)

^e INSERM   (France)

Author keywords

Disseminated intravascular coagulation; Dysfibrinogen; Fibrinogen; Mutation

Indexed keywords

ARGININE; BATROXOBIN; DNA; FIBRIN; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOPEPTIDE; HISTIDINE; MUTANT PROTEIN; THROMBIN;

ADULT; ARTICLE; CASE REPORT; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA SEQUENCE; DYSFIBRINOGENEMIA; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; IMMUNOASSAY; LIGHT SCATTERING; PARTIAL THROMBOPLASTIN TIME; POINT MUTATION; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTHROMBIN TIME; THROMBIN TIME;

EID: 0030657589     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199710000-00010     Document Type: Article

References (12)

1. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SCC subcomittee on fibrinogen. Thromb Haemost 1995; 73: 151-161.
2. Ebert RF. Index of Variant Human Fibrinogens. Boca Raton, Ann Arbor, Boston: CRC Press, 1991.
3. McDonagh J, Carrell N, Lee MH. Dysfibrinogenemia and other disorders of fibrinogen structure and function. In: Colman RW, Hirsh J, Marder VJ Salzman EW, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Company, 1994; 314-334.
4. Denninger MH, Finlayson JS, Reamer LA, Parquet-Gernez A, Goudemant M, Menache D. Congenital dysfibrinogenemia: fibrinogen Lille. Thromb Res 1978; 13: 453-466.
5. Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS. Fibrinogen Bethesda: a congenital dysfibrinogenemia with delayed fibrinopeptide release. J Clin Invest 1971; 50: 1819-1830.
6. Belitser VA, Varetskaja TV, Malneva GV. Fibrinogen-fibrin interaction. Biochim Biophys Acta 1968; 154: 367-375.
7. Bertina RM, Koeleman PC, Koster T, Rosendaal FR, Dirven RJ, Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67.
8. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-3703.
9. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylene-tetrahydrofolate reductase. Nature Genet 1995; 10: 111-113.
10. Siebenlist KR, Prchal JT, Mosesson MW. Fibrinogen Birmingham: a heterozygous dysfibrinogenemia (AαArg His) containing heterodimeric molecules. Blood 1988; 71: 613-618.
11. Galanakis DK. Inherited dysfibrinogenemia: emerging abnormal structure associations with pathologic and nonpathologic dysfunctions. Sem Thromb Hemost 1993; 19: 386-395.
12. Samama MM, Haverkate F. Hereditary dysfibrinogenemia, afibrinogenemia, hypofibrinogenemia and thrombosis. In: Seghatchian MJ, Samama MM, Hecker SP, eds. Hypercoagulable states. Fundamental Aspects, Acquired Disorders, and Congenital Thrombophilia. Boca Raton, New York, London, Tokyo: CRC Press, 1996; 379-384.